Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Aloka Chakravarty"'
Autor:
Sarah E. Vititoe, Imaani J. Easthausen, Tamar Lasky, Aloka Chakravarty, Marie C. Bradley, Laura M. Roe, Nicolle M. Gatto, Andrew R. Weckstein, Elizabeth M. Garry
Publikováno v:
PLoS ONE, Vol 17, Iss 9 (2022)
Objective To describe differences by race and ethnicity in treatment patterns among hospitalized COVID-19 patients in the US from March-August 2020. Methods Among patients in de-identified Optum electronic health record data hospitalized with COVID-1
Externí odkaz:
https://doaj.org/article/68193dbe7e794c238c70ee568ad8b89c
Autor:
Tamar, Lasky, Aloka, Chakravarty
Publikováno v:
Journal of Biopharmaceutical Statistics. :1-6
Unique challenges pertain when studying children, although many research principles are the same as those when studying adult populations. This truism extends to the use of real-world data (RWD). RWD are particularly relevant to pediatrics because th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d7333f0b840b26071c11aaf8138cf34
https://doi.org/10.1080/10543406.2022.2152834
https://doi.org/10.1080/10543406.2022.2152834
Autor:
Elizabeth M. Garry, Andrew R. Weckstein, Kenneth Quinto, Marie C. Bradley, Tamar Lasky, Aloka Chakravarty, Sandy Leonard, Sarah E. Vititoe, Imaani J. Easthausen, Jeremy A. Rassen, Nicolle M. Gatto
Publikováno v:
Pharmacoepidemiology and Drug Safety. 31:721-728
Algorithms for classification of inpatient COVID-19 severity are necessary for confounding control in studies using real-world data.Using Healthverity chargemaster and claims data, we selected patients hospitalized with COVID-19 between April 2020 an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8a827be4912cdb8dd7a4a3a7a66f32c8
https://doi.org/10.1002/pds.5436
https://doi.org/10.1002/pds.5436
Autor:
Sue Jane Wang, Suzanne Hendrix, Klaus Romero, Aloka Chakravarty, John-Michael Sauer, Samuel P. Dickson, Lisa M. McShane, Robin Mogg
Publikováno v:
Biomarkers in Medicine
Qualification of a biomarker for use in a medical product development program requires a statistical strategy that aligns available evidence with the proposed context of use (COU), identifies any data gaps to be filled and plans any additional resear
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ada180c1e3ade7afb533f79ed6c4acc
http://europepmc.org/articles/PMC8293027
http://europepmc.org/articles/PMC8293027
Publikováno v:
Simultaneous Global New Drug Development ISBN: 9781003109785
Simultaneous Global New Drug Development
Simultaneous Global New Drug Development
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::12aafa1d2e9dc5ad3d51fc1ef8778ab0
https://doi.org/10.1201/9781003109785-5
https://doi.org/10.1201/9781003109785-5
Autor:
Andrew Weckstein, Aloka Chakravarty, Elizabeth M. Garry, Jeremy A. Rassen, Sarah E Vititoe, Sandy Leonard, Imaani Easthausen, Kenneth Quinto, Tamar Lasky, Nicolle M. Gatto
STRUCTURED ABSTRACTImportanceAlgorithms for classification of inpatient COVID-19 severity are necessary for confounding control in studies using real-world data (RWD).ObjectiveTo explore use of electronic health record (EHR) data to inform an adminis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::01f79901c004de8f7c82e894a2f8fe8f
https://doi.org/10.1101/2021.10.04.21264513
https://doi.org/10.1101/2021.10.04.21264513
Autor:
David Martin, Alexander M. Walker, Mark Levenson, Simone P. Pinheiro, Susan R. Heckbert, Jennifer C. Nelson, Sengwee Toh, Aloka Chakravarty, Susan Gruber, Bruce M. Psaty, Christian G. Reich
Publikováno v:
Pharmacoepidemiology and Drug Safety. 25:973-981
BACKGROUND: We reviewed the results of the Observational Medical Outcomes Research Partnership (OMOP) 2010 Experiment in hopes of finding examples where apparently well-designed drug studies repeatedly produce anomalous findings. OMOP had applied tho
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ee1591d3110978d77523dc88770ac7a7
https://doi.org/10.1002/pds.4065
https://doi.org/10.1002/pds.4065
Autor:
Sarmistha Sanyal, Marianne H Noone, Susan McCune, James Kaiser, ShaAvhrée Buckman-Garner, Aloka Chakravarty, Shashi Amur
Publikováno v:
Biomarkers in Medicine. 9:1095-1105
The traditional route for regulatory acceptance of biomarkers in drug development is through submission of biomarker data in drug approval submissions in the context of a single drug development program. The US FDA's Critical Path Initiative called f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a4ebc21217fdedd443363b215c7a61d
https://doi.org/10.2217/bmm.15.90
https://doi.org/10.2217/bmm.15.90
Autor:
Susan, Gruber, Aloka, Chakravarty, Susan R, Heckbert, Mark, Levenson, David, Martin, Jennifer C, Nelson, Bruce M, Psaty, Simone, Pinheiro, Christian G, Reich, Sengwee, Toh, Alexander M, Walker
Publikováno v:
Pharmacoepidemiology and drug safety. 25(9)
We reviewed the results of the Observational Medical Outcomes Research Partnership (OMOP) 2010 Experiment in hopes of finding examples where apparently well-designed drug studies repeatedly produce anomalous findings. OMOP had applied thousands of de
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::8137f5539927781dfb652401ce9ad916
https://pubmed.ncbi.nlm.nih.gov/27418432
https://pubmed.ncbi.nlm.nih.gov/27418432
Publikováno v:
Statistics in Biopharmaceutical Research. 3:569-576
In the current era of personalized medicine, there has been an increased interest in biomarkers as a classifier for patient risk cohorts as well as a predictor of success for a therapeutic intervention. They hold promise to better screen patients who
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fe66e69ff4e23f75ab70148b22b4a9ec
https://doi.org/10.1198/sbr.2011.09026
https://doi.org/10.1198/sbr.2011.09026